Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of October 2025. The filing details a share repurchase executed on September 30, 2025, pursuant to a non-discretionary agreement with BNP Paribas SA. The shares acquired are held as Treasury shares.
Key Financial Metrics
The filing provides specific data regarding the share buyback transaction but does not contain revenue, profit, cash flow, margin, or debt figures.
- Shares Purchased: 305,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,521.00p; highest price paid was 1,591.00p.
- Volume-Weighted Average Price (VWAP): 1,548.83p.
- Treasury Shares Held: 247,769,844 ordinary shares following the purchase.
- Shares in Issue: 4,067,637,496 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,067,637,496.
- Treasury Voting Rights Percentage: 6.09%.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in the Company's Treasury share holdings. Since September 30, 2025, the Company has purchased 305,000 ordinary shares. The filing text does not provide comparative financial data for prior periods to assess material changes in operating performance.
Guidance, Outlook, and Risks
The filing confirms the purchase forms part of the Company's existing buyback programme. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q2 Results for 2025. No specific new guidance or outlook is provided in this document.
Investor Verification Checklist
- Verify the total cost of the buyback programme and remaining authorization limits.
- Confirm the impact of the 6.09% Treasury share holding on earnings per share (EPS) calculations.
- Review the referenced "Risk Factors" in the 2024 Form 20-F and Q2 2025 results for context on forward-looking statements.
- Check subsequent filings for updates on the buyback programme status and total shares repurchased.